CORCEPT THERAPEUTICS INC
CORT evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $12.37B
- Lead Asset:
- korlym (Approved)
What it means
What to watch
Prepared research question
What matters most for CORT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CORT
Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing selective glucocorticoid receptor antagonists for severe endocrinologic, oncologic, metabolic, and neurologic disorders.
Key risk: Single product revenue concentration
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 18 clinical trials · 1 catalyst · 2 FDA decisions for CORCEPT THERAPEUTICS INC.
Similar companies
Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing selective glucocorticoid receptor antagonists for severe endocrinologic, oncologic, metabolic, and neurologic disorders.
- Received FDA approval for Lifyorli (relacorilant) plus nab-paclitaxel in March 2026 for platinum-resistant ovarian cancer, the first approved selective glucocorticoid receptor antagonist [news].
- Reported cash & equivalents of $111.0M, total revenue of $256.1M, and net income of $43.0M as of 2026-06-30 [sec].
- Pivotal Phase 3 ROSELLA trial met dual primary endpoints of progression-free and overall survival [sec · filed 2026-04-17].
- Submitted a marketing authorization application (MAA) to the EMA in October 2025, with a decision expected in Q4 2026 [sec_mda · as of 2026-07-29].
- Completed enrollment in MOMENTUM (hypercortisolism in resistant hypertension) and MONARCH (MASH) trials [sec · filed 2026-04-17].
What works
- First-in-class FDA-approved selective glucocorticoid receptor antagonist (Lifyorli) provides a differentiated oncology product with survival data [news].
- Strong cash position of $111.0M as of 2026-06-30 supports ongoing R&D and commercialization [sec].
- Positive Phase 3 ROSELLA data led to NCCN guideline inclusion as a preferred regimen [news].
- Multiple ongoing Phase 2 trials in ovarian, endometrial, and pancreatic cancers diversify pipeline [sec · filed 2026-04-17].
What to weigh
- Reliance on a single approved product (Lifyorli) for near-term revenue concentration risk [news].
- EMA decision on relacorilant is pending and not guaranteed, with potential EU market access delay [sec_mda · as of 2026-07-29].
- Patent expiry for mifepristone in 2038 may affect related product exclusivity [catalyst].
- Clinical trial enrollment and regulatory timelines for other pipeline assets (e.g., nenocorilant) remain uncertain [sec · filed 2026-04-17].
From the filings
Quoted directly from source documents.
FDA approval of Lifyorli for platinum-resistant ovarian cancer
“Corcept Therapeutics recently received U.S. FDA approval for Lifyorli (relacorilant) plus nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior therapies including bevacizumab.”
News · March 28, 2026
Phase 3 ROSELLA trial met dual primary endpoints
“our pivotal Phase 3 trial of relacorilant combined with the chemotherapy medication nab-paclitaxel in patients with platinum-resistant ovarian cancer, meeting both of the trial's dual primary endpoints (progression-free and overall survival).”
SEC filings · April 17, 2026
EMA MAA submitted with decision expected Q4 2026
“In October 2025, we submitted a marketing authorization application ("MAA") to the EMA seeking approval in the EU, with an EMA decision expected in the fourth quarter of 2026.”
SEC MD&A · July 29, 2026
Catalyst timeline
- 2038-08-22 · Patent_Expiry · MIFEPRISTONE — Patent expiry for mifepristone (NDA202107) may open the market to generic competition, affecting Corcept's related product exclusivity.
Risks & what to watch (4)›
Key risks
- Single product revenue concentration — Near-term revenue depends heavily on Lifyorli, with no other approved products to diversify [news].
- EMA approval uncertainty — EU marketing authorization decision for relacorilant is pending and may be delayed or denied [sec_mda · as of 2026-07-29].
- Patent expiry for mifepristone — Patent expiry in 2038 could affect related product exclusivity and competitive landscape [catalyst].
- Pipeline stage risk — Other pipeline candidates (e.g., nenocorilant) are in early Phase 1/2 trials with no guarantee of success [sec · filed 2026-04-17].
What to watch
- EMA decision on relacorilant MAA expected in Q4 2026 [sec_mda · as of 2026-07-29].
- Commercial uptake and reimbursement of Lifyorli following FDA approval and NCCN inclusion [news].
- Data readouts from ongoing Phase 2 trials in platinum-sensitive ovarian, endometrial, and pancreatic cancers [sec · filed 2026-04-17].
- Results from MOMENTUM and MONARCH trials evaluating hypercortisolism and MASH [sec · filed 2026-04-17].
Sources: Catalysts · News · SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run CORCEPT THERAPEUTICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CORCEPT THERAPEUTICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.26 · 12% dilution
Lead: Approved
2 candidates
1 upcoming, next in ~4330d
0 buys · 58 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 12.9%
- Days to cover
- 9.6
- Shares short
- 10,710,814
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CORT short interestGovernance
Frequently asked questions
What is the AI investment thesis for CORCEPT THERAPEUTICS INC?
Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing selective glucocorticoid receptor antagonists for severe endocrinologic, oncologic, metabolic, and neurologic disorders.
What is CORCEPT THERAPEUTICS INC's lead drug candidate?
CORCEPT THERAPEUTICS INC's most advanced tracked candidate is korlym (Approved) for Cushing's syndrome (hypercortisolism).
What is CORCEPT THERAPEUTICS INC's next catalyst?
CORCEPT THERAPEUTICS INC's next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA202107" — expected August 22, 2038.
Who is the CEO of CORCEPT THERAPEUTICS INC?
Dr. Joseph K. Belanoff M.D. is the chief executive officer of CORCEPT THERAPEUTICS INC (CORT).
Where is CORCEPT THERAPEUTICS INC headquartered?
CORCEPT THERAPEUTICS INC (CORT) is headquartered in Redwood City, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.